- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04261972
Cell-free DNA in Hereditary And High-Risk Malignancies (CHARM)
February 14, 2022 updated by: University Health Network, Toronto
Early Detection of Cancer in High-risk Patients Through Cell-free DNA
The goal of this study is to develop an effective, sensitive blood test that can detect early tumours in patients with known or suspected hereditary cancer syndromes (HCS).
If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection.
The study will also use questionnaires and interviews to understand how patients feel about incorporating these tests into routine medical care, and the perceptions of the medical value of test results.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The objective of this protocol is to develop a method to detect early signs of cancer in 'previvors' (people with HCS that do not yet have a cancer diagnosis).
This will enable prediction of cancer onset so that patients and their doctors can make decisions to treat or prevent the cancers.
HCS patients will be recruited from across Canada to provide blood samples before and after cancer diagnosis.
In parallel, there will be development of a circulating tumour DNA (ctDNA) -based test to detect early stage cancer and evaluation on the cost-effectiveness and feasibility of integrating such screening protocols into routine clinical care.
In concert, consultation with patients and health care providers will occur to create recommendations for use within clinical care.
Study Type
Observational
Enrollment (Anticipated)
1500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Leslie Oldfield, MSc.
- Phone Number: 613-532-9847
- Email: charm@uhnresearch.ca
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Recruiting
- BC Cancer Agency
-
Contact:
- Intan Schrader, MD
- Phone Number: 672198 604-877-6000
- Email: ischrader@bccancer.bc.ca
-
Contact:
- Sara Singh
- Email: sara.singh@bccancer.bc.ca
-
Principal Investigator:
- Intan Schrader, MD
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Recruiting
- Eastern Health
-
Contact:
- Lesa Dawson
- Phone Number: 709-749-9686
- Email: lmdawson@mun.ca
-
Contact:
- Stacy Whittle
- Email: stacy.whittle@easternhealth.ca
-
Principal Investigator:
- Lesa Dawson, MD
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Recruiting
- IWK Health Centre
-
Contact:
- Lynette Penney
- Email: lynette.penney@iwk.nshealth.ca
-
Principal Investigator:
- Lynette Penney, MD
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- University Health Network
-
Contact:
- Raymond Kim, MD
- Phone Number: 4220 416-586-4800
- Email: raymond.kim@uhn.ca
-
Contact:
- Leslie Oldfield, MSc
- Phone Number: 613-532-9847
- Email: leslie.oldfield@uhnresearch.ca
-
Toronto, Ontario, Canada, M5G 1X5
- Recruiting
- Sinai Health System
-
Contact:
- Raymond Kim, MD
- Phone Number: 4220 416-586-4800
- Email: raymond.kim@uhn.ca
-
Toronto, Ontario, Canada, M5S 1B2
- Recruiting
- Women's College Hospital
-
Contact:
- Gabby Ene
-
Contact:
- Phone Number: 3969 (416)-946-4501
- Email: gabrielle.ene@uhnresearch.ca
-
Principal Investigator:
- Marcus Bernardini, MD
-
Principal Investigator:
- Michelle Jacobson, MD
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- Jewish General Hospital
-
Contact:
- William Foulkes
- Email: william.foulkes@mcgill.ca
-
Contact:
- Mark Basik
- Email: mark.basik@mcgill.ca
-
Principal Investigator:
- William Foulkes, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The population to be studied includes:
- Any individual that underwent clinical genetic testing for hereditary breast and ovarian cancer syndrome or Lynch Syndrome and was found to carry a detectable variant that is likely pathogenic or pathogenic.
- Any individual with a suspected cancer predisposition that has not yet received genetic testing.
- Any individual who received negative genetic test results but has a strong personal or family history of cancer.
Description
Inclusion Criteria:
- Individual with any known or suspected hereditary cancer predisposition (i.e. individuals with an identified pathogenic or likely pathogenic variant in a cancer predisposition gene and/or a family history of cancer without an identified gene mutation) at any stage in their cancer journey (ie: cancer survivor, unaffected with cancer, current cancer patient).
- Individual must be greater than 18 years of age
- Individual must speak English or French to participate in the qualitative interview and/or survey
Exclusion Criteria:
1. Individuals that do not meet the outlined inclusion criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CHARM
Patients identified with hereditary breast and ovarian cancer syndrome (germline BRCA1 or BRCA2 carrier) or Lynch syndrome (germline variant in EPCAM, MLH1, MSH2, MSH6, or PMS2).
|
NGS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collection of biospecimens from 1500 HSC carriers.
Time Frame: up to 4 years
|
Facilitate and streamline the collection, banking, and annotation of plasma samples and tumour tissue (if applicable) across Canada.
|
up to 4 years
|
Collection of clinical data from 1500 HSC carriers.
Time Frame: up to 4 years
|
Extract clinical data for all study participants from electronic medical records.
Data collection will include family history and medical history.
|
up to 4 years
|
Detection of early stage cancer in HCS patients using cfDNA.
Time Frame: up to 4 years
|
Detect concentration of cfDNA circulating in the blood by shallow whole-genome sequencing, targeted panel analysis, and cfMeDIP.
|
up to 4 years
|
Evaluation of the clinical utility of a cfDNA test for HSC patients.
Time Frame: up to 4 years
|
Conduct qualitative interviews with healthcare providers and patients.
|
up to 4 years
|
Evaluation of the optimal implementation of cfDNA in clinical practice.
Time Frame: up to 4 years
|
Conduct a discrete choice experiment survey with HCS patient and providers.
|
up to 4 years
|
Evaluation of cfDNA test implementation through cost-effectiveness analysis of cfDNA versus standard of care.
Time Frame: up to 4 years
|
Conduct economic modelling using the economic evaluation guidelines from the Canadian Agency for Drugs and Technologies in Health.
|
up to 4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Raymond Kim, MD, Princess Margaret Cancer Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 1, 2018
Primary Completion (ANTICIPATED)
October 1, 2022
Study Completion (ANTICIPATED)
October 1, 2023
Study Registration Dates
First Submitted
January 2, 2020
First Submitted That Met QC Criteria
February 7, 2020
First Posted (ACTUAL)
February 10, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 15, 2022
Last Update Submitted That Met QC Criteria
February 14, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1655
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Cancer Syndrome
-
Myriad Genetic Laboratories, Inc.Myriad Genetics, Inc.CompletedHereditary CancerUnited States
-
InheRET, IncUniversity of MichiganEnrolling by invitationHereditary Cancer-Predisposing SyndromeUnited States
-
Weill Medical College of Cornell UniversityRecruitingGynecologic Cancer | Hereditary Cancer SyndromeUnited States
-
Institut Claudius RegaudUnknownHereditary Breast and Ovarian Cancer | Hereditary Cancer Syndrome | Hereditary Colorectal Endometrial Cancer SyndromeFrance
-
Scripps HealthJ. Craig Venter InstituteCompletedLi-Fraumeni Syndrome | Hereditary Cancer Syndromes | TP53 Gene Germline Mutation CarrierUnited States
-
University Health Network, TorontoActive, not recruitingMutation | Hereditary Cancer Syndrome | High-Risk | Germline MutationCanada
-
University of Illinois at ChicagoWithdrawn
-
University of Texas Southwestern Medical CenterRecruiting
-
M.D. Anderson Cancer CenterRecruiting
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Baylor College of Medicine; City of Hope Medical...RecruitingTP53 Gene Mutation | Li-Fraumeni Syndrome | Hereditary Cancer Syndrome | Mosaicism | Clonal HematopoiesisUnited States
Clinical Trials on Next generation sequencing (NGS)
-
Jagiellonian UniversityRecruiting
-
University Hospital TuebingenRecruitingRare Diseases | Genetic PredispositionGermany
-
Na Homolce HospitalCzech Academy of SciencesCompletedVascular AneurysmCzechia
-
University Hospital TuebingenCharite University, Berlin, Germany; RWTH Aachen University; Medical University...Not yet recruiting
-
Fudan UniversitySouthern Medical University, ChinaCompletedColorectal Cancer | AdenomaChina
-
Imperial College London Diabetes CentreUnknownFamilial HypercholesterolemiaUnited Arab Emirates
-
Fudan UniversityUnknownColorectal Cancer | Lymph Node MetastasesChina
-
Munich Leukemia LaboratoryIllumina, Inc.RecruitingLeukemia | Rare Diseases | Refractory Lymphoma | Hematologic Malignancy | Refractory Leukemia | Unknown Primary TumorsGermany
-
Addario Lung Cancer Medical InstituteDana-Farber Cancer InstituteActive, not recruitingNon-Small Cell Lung CancerUnited States
-
Institut National de la Santé Et de la Recherche...Institut Bergonié; Plateforme labellisée Inca - Institut Bergonié, Bordeaux; Plateforme... and other collaboratorsCompletedSoft Tissue Sarcoma | Colorectal CarcinomaFrance